Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

Ranoux D, Attal N, Morain F, Bouhassira D.

Ann Neurol. 2008 Sep;64(3):274-83. doi: 10.1002/ana.21427. Erratum in: Ann Neurol. 2009 Mar;65(3):359.

2.

Neuropathic pain: a clinical perspective.

Baron R.

Handb Exp Pharmacol. 2009;(194):3-30. doi: 10.1007/978-3-540-79090-7_1. Review.

PMID:
19655103
3.

[Botulinum toxin and painful peripheral neuropathies: what should be expected?].

Ranoux D.

Rev Neurol (Paris). 2011 Jan;167(1):46-50. doi: 10.1016/j.neurol.2010.11.001. Epub 2010 Dec 30. Review. French.

PMID:
21194720
4.

Pharmacologic management part 1: better-studied neuropathic pain diseases.

Backonja MM, Serra J.

Pain Med. 2004 Mar;5 Suppl 1:S28-47. Review.

PMID:
14996228
5.

Neuropathic pain in leprosy.

Haanpää M, Lockwood DN, Hietaharju A.

Lepr Rev. 2004 Mar;75(1):7-18. Review.

PMID:
15072122
6.

Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation.

Intiso D, Basciani M, Santamato A, Intiso M, Di Rienzo F.

Toxins (Basel). 2015 Jun 30;7(7):2454-80. doi: 10.3390/toxins7072454. Review.

7.

Botulinum toxin type A (BOTOX) for treatment of migraine.

Binder WJ, Brin MF, Blitzer A, Pogoda JM.

Dis Mon. 2002 May;48(5):323-35. Review.

PMID:
12195263
8.

Botulinum toxin for pain.

Casale R, Tugnoli V.

Drugs R D. 2008;9(1):11-27. Review.

PMID:
18095750
9.

Peripheral neuropathic pain: from mechanisms to symptoms.

Baron R.

Clin J Pain. 2000 Jun;16(2 Suppl):S12-20. Review.

PMID:
10870735
10.

Neuropathic pain: the clinical syndrome revisited.

Bouhassira D.

Acta Neurol Belg. 2001 Mar;101(1):47-52. Review.

PMID:
11379276
11.

Mechanisms of neuropathic pain and their implications for the design of clinical trials.

Rowbotham MC.

Neurology. 2005 Dec 29;65(12 Suppl 4):S66-73. Review.

PMID:
16385106
12.

[Treatment of the spastic drop foot with botulinum toxin type A in adult patients].

Voller B, Földy D, Hefter H, Auff E, Schnider P.

Wien Klin Wochenschr. 2001;113 Suppl 4:25-9. Review. German.

PMID:
15506049
13.

Evidence for antinociceptive activity of botulinum toxin type A in pain management.

Aoki KR.

Headache. 2003 Jul-Aug;43 Suppl 1:S9-15. Review.

PMID:
12887389
14.

The use of botulinum toxin in the pelvic floor for women with chronic pelvic pain-a new answer to old problems?

Abbott J.

J Minim Invasive Gynecol. 2009 Mar-Apr;16(2):130-5. doi: 10.1016/j.jmig.2008.11.006. Epub 2009 Jan 22. Review.

PMID:
19167273
15.

Reducing and eliminating neuropathic pain.

Santiago-Figueroa J, Kuffler DP.

P R Health Sci J. 2009 Dec;28(4):289-300. Review.

PMID:
19999236
16.

Pharmacotherapy for neuropathic pain.

Jackson KC 2nd.

Pain Pract. 2006 Mar;6(1):27-33. Review.

PMID:
17309706
17.

Pharmacological management of neuropathic pain in older adults: an update on peripherally and centrally acting agents.

McGeeney BE.

J Pain Symptom Manage. 2009 Aug;38(2 Suppl):S15-27. doi: 10.1016/j.jpainsymman.2009.05.003. Review.

PMID:
19671468
18.

Immune and inflammatory mechanisms in neuropathic pain.

Moalem G, Tracey DJ.

Brain Res Rev. 2006 Aug;51(2):240-64. Epub 2006 Jan 4. Review.

PMID:
16388853
19.

Emerging trends in the management of neuropathic pain.

McCleane G.

Expert Rev Neurother. 2005 Sep;5(5):617-23. Review.

PMID:
16162085
20.

Painful peripheral neuropathy and its nonsurgical treatment.

Wolfe GI, Trivedi JR.

Muscle Nerve. 2004 Jul;30(1):3-19. Review.

PMID:
15221874

Supplemental Content

Support Center